Definition And Composition
- Contains live attenuated Sabin strains.
- Derived by repeated passage in monkey kidney cell cultures.
- Stabilized utilizing magnesium chloride.
| Formulation Type | Composition | Clinical Application |
|---|
| Trivalent | Serotypes 1, 2, and 3 | Discontinued globally in 2016 preventing type 2 outbreaks. |
| Bivalent | Serotypes 1 and 3 | Current standard for routine immunization programs. |
| Monovalent | Single serotype (1, 2, or 3) | Deployed specifically for outbreak responses. |
| Novel Type 2 | Genetically stabilized serotype 2 | Outbreak response minimizing reversion risk. |
Mechanism Of Immunity And Pathophysiology
- Infects intestinal mucosa upon oral administration.
- Multiplies extensively within mucosal cells.
- Induces robust mucosal immunity mediated by secretory immunoglobulin A.
- Reduces viral shedding and limits feco-oral transmission.
- Provides indirect herd immunity protecting unvaccinated community members.
- Systemic immunity generated but mucosal response remains relatively short-lived compared to inactivated alternatives.
Factors Influencing Immunogenicity
- Maternal antibodies potentially neutralize organism before mucosal infection occurs.
- Birth dose enhances seroconversion before enteric pathogens establish interference.
- Seroconversion rates appear lower in developing regions.
- Affected by competition from other enteroviruses, concomitant diarrhea, and zinc deficiency.
- Type 2 serotype proves most immunogenic, interfering with types 1 and 3 responses.
Dosage And Administration Schedule
- Administer 2 drops (0.1 mL) orally directly into mouth.
- Requires multiple doses ensuring adequate seroconversion.
Routine Schedule
- Zero dose: Administer at birth or within 15 days.
- Primary series: Administer at 6, 10, and 14 weeks.
- Booster doses: Administer at 15 to 18 months.
Supplementary Immunization Activities
- National immunization days utilize oral vaccine for all children under 5 years.
- Mopping-up campaigns conduct house-to-house administration targeting reservoirs.
- Coadministration remains safe with other childhood vaccines without compromising efficacy.
Storage And Cold Chain Management
- Exhibits high sensitivity to heat and temperature fluctuations.
- Maintain frozen at -15°C to -25°C for long-term bulk storage.
- Store at +2°C to +8°C for maximum 6 months after thawing.
- Monitor potency strictly utilizing vaccine vial monitors on labels.
Adverse Effects And Safety Issues
Vaccine-Associated Paralytic Poliomyelitis
- Defined as paralytic polio occurring in vaccinee or close contact.
- Attributed to genetic mutation of attenuated vaccine strain in human gut.
- Incidence rate equals 1 per 1.5 to 2.9 million administered doses.
- Risk peaks exponentially following first administered dose.
Circulating Vaccine-Derived Poliovirus
- Emerges predominantly in regions with low vaccine coverage.
- Attenuated virus regains neurovirulence and transmissibility during prolonged replication.
- Type 2 strain causes majority (90%) of circulating outbreaks globally.
Contraindications
- Inherited or acquired immunodeficiency disorders.
- Symptomatic human immunodeficiency virus infection.
- Avoid usage in household contacts of immunocompromised patients.
- Withhold routine administration during pregnancy.
- Breastfeeding and mild diarrhea constitute safe administration scenarios.
Polio Endgame Strategy
- Switched globally from trivalent to bivalent vaccine in April 2016.
- Sequential schedule involves prior inactivated vaccine administration minimizing vaccine-associated paralysis risk.
- Novel genetically stable strains introduced to prevent subsequent type 2 outbreaks.
